Diabetes management tools and smartphones have long worked closely to help users with this chronic disease better manage their health. Now, a smartphone maker is forging a partnership with one of the biggest names in the diabetes industry. At the 75th Annual Scientific Meeting of the American Diabetes Association in Boston, Medtronic announced that it will work with Samsung Electronics to increase the functionality of the Android-based mobile health management platform for diabetics and their healthcare providers. Officials say the strong collaboration will develop an Internet app that enables Samsung devices to be paired with Medtronic's MiniMed Connect platform, linking diabetes patients, insulin pumps, blood glucose monitoring systems and healthcare providers. I compiled the details of Medtronic and Samsung's collaboration on diabetes management to see how they creatively apply new technologies to achieve a breakthrough in the diabetes experience.

The impact of strong alliances is enormous. This Internet medical solution enables diabetics and their caregivers to monitor blood glucose levels and manage insulin injections in real time via mobile devices, improving the lifestyle habits of people with diabetes in both short-term and long-term, reducing treatment costs and Dangerous complications.

"Samsung is committed to bringing innovation to the healthcare industry with its deep understanding of how people apply technology," David Rhew, chief medical officer and head of the medical and fitness department at Samsung Electronics (USA), at the ADA conference press conference on June 5th. Said, “Patients are looking for better ways to monitor their illness while enjoying a higher quality of life. We are excited to work with Medtronic to develop a diabetes management solution that will bring more active diabetes patients. Changes, and greater autonomy."

“By addressing the social and emotional problems of people with diabetes and improving their lifestyles, people around the world will be able to experience the most advanced methods of controlling diabetes,” said Alejandro, Vice President and General Manager, Medtronics Intensive Management. Galindo added, "Medtronic's goal is to transform diabetes with leading-edge technology, big data and informatics by providing world-class integrated care services. Our collaboration with Samsung is the key to more convenient and rigorous access to diabetes data. In one step, we will work together to provide greater freedom and healthier body for people with diabetes."

Samsung-Medtronic's collaboration is not the only Internet medical news related to diabetes this month. On June 3, Glooko announced that it has partnered with Dexcom, which develops a dynamic blood glucose monitoring platform, and Insulet, which has developed the OmniPod insulin management system, to create a platform for collecting and analyzing diabetes medical data, which can be used by different devices. Glooko executives said that more than 30 blood glucose monitor data from Dexcom's CGM and Insulet's OmniPod, as well as data from many mobile devices equipped with Apple and Android, will be imported into the Glooko platform. "The integration of Internet medical data will have a significant impact on the clinical care of people with diabetes," said Howard Wolpert of the Joslin Diabetes Center in a press release from Glooko. "We are working with Glooko to create Glooko. Data for Joslin HypoMap, and Glooko will continue to add device data and comprehensive information reports, providing clinical insights that cannot be derived from currently available download data to help more patients recognize the benefits of CGM and pump insulin, and Help clinicians provide more effective and effective care,” he continued.

Before Medtronic announced its partnership with Samsung, its MiniMed Connect device was approved in the US FDA's June 5 announcement. MiniMed Connect can safely transfer data and BGM data from the MiniMed insulin pump to the smartphone app and to the web dashboard for real-time observation of blood glucose and insulin information. If the alarm in the insulin pump is not processed or the reading reaches a dangerous level, the system can also send a text message to the designated caregiver.

“The participation of people with diabetes, relatives and medical providers is key to improving the quality of life of people with diabetes. The application of MiniMed Connet enables the entire care team to access critical data on diabetes and help people make decisions that make better outcomes.” Annette Brüls, vice president and general manager of Medtronic's Diabetes Services and Solutions division, said in an independent press release announcing FDA approval that "MiniMed Connect is an important part of our vision strategy. With it, Medtronic is moving towards a comprehensive diabetes management. The company's goal is a step forward. The Connect platform shows the world how we can use leading technology, data and information to achieve better treatment decisions and care for people with diabetes. We hope it will make it easier for more people. Manage diseases and optimize treatment options to enable people with diabetes to gain greater freedom and healthier bodies."

Medtronic’s actions are far more than that. The company also announced a partnership with BD (BD) to develop a new insulin pump infusion device using BD FlowSmart technology to improve the consistency of insulin delivery through pumps connected to the body of diabetic patients. The infusion set has been approved in the United States and Canada and has been submitted to the EU for approval and is expected to enter the market next year. In addition, the company uses the MiniMed platform to develop an artificial pancreas in a series of European studies.

Pacific Mackerel

Pacific Mackerel

Pacific Mackerel

ZHEJIANG EVERNEW SEAFOOD CO.,LTD , https://www.evernewseafood.com